About Retinaldehyde-binding protein 1
Retinaldehyde-binding protein 1 (RLBP1) is a protein
from Homo sapiens identified by UniProt accession
P12271, 317 residues long.
MolForge cross-references it against 0 known binders and
141 disease associations.
Target properties
| Protein name | Retinaldehyde-binding protein 1 |
| UniProt accession | P12271 |
| Gene | RLBP1 |
| Organism | Homo sapiens |
| Length | 317 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (141)
Diseases linked to this target (Open Targets).
- fundus albipunctatus · score 0.71
- retinitis pigmentosa · score 0.67
- Bothnia retinal dystrophy · score 0.66
- Newfoundland cone-rod dystrophy · score 0.63
- retinitis punctata albescens · score 0.63
- Retinal dystrophy · score 0.52
- Joubert syndrome and related disorders · score 0.48
- autosomal recessive retinitis pigmentosa · score 0.46
- Posterior column ataxia - retinitis pigmentosa · score 0.37
- RLBP1-related retinopathy · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P12271-F1 | alphafold | PREDICTED | 91.52 | — |
Amino-acid sequence (317 residues)
MSEGVGTFRM VPEEEQELRA QLEQLTTKDH GPVFGPCSQL PRHTLQKAKD ELNEREETRE EAVRELQEMV QAQAASGEEL AVAVAERVQE KDSGFFLRFI RARKFNVGRA YELLRGYVNF RLQYPELFDS LSPEAVRCTI EAGYPGVLSS RDKYGRVVML FNIENWQSQE ITFDEILQAY CFILEKLLEN EETQINGFCI IENFKGFTMQ QAASLRTSDL RKMVDMLQDS FPARFKAIHF IHQPWYFTTT YNVVKPFLKS KLLERVFVHG DDLSGFYQEI DENILPSDFG GTLPKYDGKA VAEQLFGPQA QAENTAF
Explore Retinaldehyde-binding protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets